Extravasation injuries

Reference

1. • Upton J
   • Mulliken J.B.
   • Murray J.E.
   Major intravenous extravasation injuries.
   Am J Surg. 1979; 137: 497-506
   • Google Scholar
2. • Cox K
   • Stuart-Harris R
   • Abdini G
   • Grygiel J
   • Raghavan D
   The management of cytotoxic-drug extravasation: guide-lines drawn up by a working party for the clinical oncological Society of Australia.
   Med J Australia. 1988; 148: 185-189
   • Google Scholar
3. • Olver I.N.
   • Schwartz M.A.
   The use of dimethylsulphoxide in limiting tissue damage caused by extravasation of doxorubicin.
   Cancer Treat Rep. 1983; 67: 407-408
   • Google Scholar
4. • Laurie S.W.S.
   • Wilson K.L.
   • Kernahan D.A.
   • Bauer B.S.
   • Vistnes L.M.
   Intravenous extravasation injuries: the effectiveness of Hyaluronidase in their treatment.
   Ann Plast Surg. 1984; 13: 191-194
   • Google Scholar
5. • Heckler F.R.
   Current thoughts on extravasation injuries.
   Clinics in Plastic Surgery. 1989; 16: 557-563
   • Google Scholar
6. • Larson D.L.
   Treatment of tissue extravasation by antitumor agents.
   Cancer. 1982; 49: 1796-1799
   • Google Scholar
7. • Larson D.L.
   What is the appropriate management of tissue extravasation by antitumor agents?.
   Plast Reconstr Surg. 1985; 75: 397-402
   • Google Scholar
8. • Reilly J.J.
   • Neifeld J.P.
   • Rosenberg S.A.
   Clinical course and management of accidental Adriamycin extravasation.
   Cancer. 1977; 40: 2053-2056
   • Google Scholar
9. • Smith R
   Prevention and treatment of extravasation.
   Br J Parenteral Therapy. 1985; 6: 114-119
   • Google Scholar
10. • Linder R.M.
    • Upton J
    • Osteen R
    Management of extensive doxorubicin hydrochloride extravasation injuries.
    J Hand Surgery. 1983; 8A: 32-38
    • Google Scholar
11. • Linder R.M.
    • Upton J
    Prevention of extravasation injuries secondary to doxorubicin.
    Postgraduate Medicine. 1985; 77: 105-114
    • Google Scholar
12. • Laughlin R.A.
    • Landeen J.M.
    • Habal M.B.
    The management of inadvertent subcutaneous Adriamycin infiltration.
    Am J Surg. 1979; 137: 408-412
    • Google Scholar
13. • Wang J.J.
    • Cortes E
    • Sinks L.F.
    • Holland J.F.
    Therapeutic effect and toxicity of Adriamycin in patients with neoplastic disease.
    Cancer. 1971; 28: 837-843
    • Google Scholar
14. • Phelps S.J.
    • Helms R.A.
    Risk factors affecting infiltration of peripheral venous lines in infants.
    J Paediatrics. 1987; 111: 384-389
    • Google Scholar
15. • Brown A.S.
    • Hoelzer D.J.
    • Piercy S.A.
    Skin necrosis from extravasation of intravenous fluids in children.
    Plast Reconstr Surg. 1979; 64: 145-150
    • Google Scholar
16. • Yosowitz P
    • Ekland D.A.
    • Shaw R.C.
    • Parsons R.W.
    Peripheral intravenous infiltration necrosis.
    Ann Surg. 1975; 182: 553-556
    • Google Scholar
17. • Gaze N.R.
    Tissue necrosis caused by commonly used intravenous infusions.
    Lancet. 1978; ii: 417-419
    • Google Scholar
18. • Bhawan J
    • Petry J
    • Rybak M.E.
    Histologic changes induced in skin by extravasation of doxorubicin (Adriamycin).
    J Cutan Pathol. 1989; 16: 158-163
    • Google Scholar
19. • Lewis G.B.H.
    • Hecker J.F.
    Radiological examination of failure of intravenous infusions.
    Br J Surg. 1991; 78: 500-501
    • Google Scholar
20. • Lewis G.B.H.
    • Hecker J.F.
    Changes in local venous tone in response to infusions of saline and dextrose solutions.
    Anaesth Intensive Care. 1984; 12: 27-32
    • Google Scholar
21. • Mostert J.W.
    The pH and osmolality of intravenously used drgus.
    JAMA. 1971; 216: 1483
    • Google Scholar
22. • Tse R.L.
    • Lee M.W.
    pH of infusion fluids: A predisposing factor in thrombophlebitis.
    JAMA. 1971; 215: 642
    • Google Scholar
23. • Dean J.C.
    • Salmon S.E.
    • Griffith K.S.
    Prevention of doxorubicin-induced hair loss with scalp hypothermia.
    NEJM. 1979; 301: 1427-1429
    • Google Scholar
24. • Garnick M
    • Israel M
    • Khetarpal V
    • Luce J
    Persistence of anthracycline levels following dermal and subcutaneous Adriamycin extravasation.
    in: Proc Am Assoc Cancer Res. 22. 1981: 173
    • Google Scholar
25. • Harris P.A.
    • Gross J.F.
    Preliminary pharmacokinetic model for Adriamycin (NSC-123127).
    Cancer Chemotherapy Reports. 1975; 59: 819-825
    • Google Scholar
26. • Dufresne R.G.
    Skin necrosis from intravenously infused materials.
    Cutis. 1987; 39: 197-198
    • Google Scholar
27. • Stetson J.B.
    • Reading G.P.
    Avoidance of vascular complications associated with use of dopamine.
    J Can Anaesth Society. 1977; 24: 727
    • Google Scholar
28. • Hecker J.F.
    Potential for extending survival of peripheral intravenous infusions.
    BMJ. 1992; 304: 619-624
    • Google Scholar
29. • Birdsall C
    • Naliboff A.R.
    How do you manage chemotherapy extravasation?.
    Am J Nursing. February 1988; : 228-230
    • Google Scholar
30. • Dorr R.T.
    Antidotes to vesicant chemotherapy extravasations.
    Blood Reviews. 1990; 4: 41-60
    • Google Scholar
31. • Dorr R.T.
    • Alberts D.S.
    • Stone A
    Cold protection and heat enhancement of doxorubicin skin toxicity in the mouse.
    Cancer Treatment Rep. 1985; 69: 431-437
    • Google Scholar
32. • Cohen F.J.
    • Manganaro J
    • Bezozo R.C.
    Identification of involved tissue during surgical treatment of doxorubicin-induced extravasation necrosis.
    J Hand Surg. 1983; 8A: 43-45
    • Google Scholar
33. • Bowers D.G.
    • Lynch J.B.
    Adriamycin extravasation.
    Plast Reconstr Surg. 1978; 61: 86-92
    • Google Scholar
34. • Banerjee A
    • Brotherston T.M.
    • Lamberty B.G.H.
    • Campbell R.C.
    Cancer chemotherapy agent induced perivenous extravasation injuries.
    Postgraduate Medicine Journal. 1987; 63: 5-9
    • Google Scholar
35. • Loth T.S.
    • Eversmann W.W.
    Treatment methods for extravasation of chemotherapeutic agents: a comparative study.
    J Hand Surg. 1986; 11A: 388-396
    • Google Scholar